MX2020000488A - Metodos y composiciones para el tratamiento del dolor usando capsaicina. - Google Patents

Metodos y composiciones para el tratamiento del dolor usando capsaicina.

Info

Publication number
MX2020000488A
MX2020000488A MX2020000488A MX2020000488A MX2020000488A MX 2020000488 A MX2020000488 A MX 2020000488A MX 2020000488 A MX2020000488 A MX 2020000488A MX 2020000488 A MX2020000488 A MX 2020000488A MX 2020000488 A MX2020000488 A MX 2020000488A
Authority
MX
Mexico
Prior art keywords
capsaicin
months
pain
methods
burning sensation
Prior art date
Application number
MX2020000488A
Other languages
English (en)
Spanish (es)
Inventor
Randall Stevens
Drazen Ostovic
Campbell James N
Hanson Peter D
Gary F Musso
Original Assignee
Centrexion Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centrexion Therapeutics Corp filed Critical Centrexion Therapeutics Corp
Publication of MX2020000488A publication Critical patent/MX2020000488A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/10—Cooling bags, e.g. ice-bags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001—Body part
    • A61F2007/0039—Leg or parts thereof
    • A61F2007/0042—Knee

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
MX2020000488A 2017-07-20 2018-07-20 Metodos y composiciones para el tratamiento del dolor usando capsaicina. MX2020000488A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762535003P 2017-07-20 2017-07-20
PCT/US2018/043094 WO2019018769A1 (en) 2017-07-20 2018-07-20 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE

Publications (1)

Publication Number Publication Date
MX2020000488A true MX2020000488A (es) 2020-10-28

Family

ID=65016186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000488A MX2020000488A (es) 2017-07-20 2018-07-20 Metodos y composiciones para el tratamiento del dolor usando capsaicina.

Country Status (11)

Country Link
US (4) US20200206166A1 (https=)
EP (1) EP3654961B1 (https=)
JP (2) JP7282736B2 (https=)
CN (1) CN111201015A (https=)
AU (1) AU2018302342B2 (https=)
BR (1) BR112020000989A2 (https=)
CA (1) CA3069540A1 (https=)
ES (1) ES3018268T3 (https=)
IL (1) IL272036B2 (https=)
MX (1) MX2020000488A (https=)
WO (1) WO2019018769A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018769A1 (en) * 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE
EP3840739B1 (en) * 2018-08-24 2025-11-12 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
CN114028540B (zh) * 2021-11-26 2023-10-17 海南鑫开源医药科技有限公司 一种具有镇痛作用的组合物、微针贴片及其制备方法以及应用
CN115006379B (zh) * 2021-12-28 2023-12-15 南京清普生物科技有限公司 一种trpv1激动剂原位膜剂组合物，及其制备方法和用途
EP4593867A2 (en) * 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US5099030A (en) 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5431914A (en) 1992-04-17 1995-07-11 Adekunle; Michael Method of treating an internal condition by external application of capsaicin without the need for systemic absorption
US5985860A (en) 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
EP0646372B1 (de) 1993-09-30 1999-03-31 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
US5762963A (en) 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
WO1998020867A1 (en) 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
US6060060A (en) 1997-01-31 2000-05-09 Bmb Patent Holding Corporation Analgesic compositions from sweet peppers and methods of use thereof
ATE219674T1 (de) 1997-03-13 2002-07-15 James N Campbell Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
EP0984781A1 (en) 1997-05-27 2000-03-15 Algos Pharmaceutical Corporation Analgesic drug composition containing a capsaicinoid and potentiator therefor
CA2442049C (en) 2001-03-22 2010-06-01 Michael J. Iadarola Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
US20030104085A1 (en) 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
JP2005538983A (ja) 2002-07-19 2005-12-22 メステックス アクチエンゲゼルシャフト 関節痛の治療のための薬剤を製造するための神経毒性物質の使用および同薬剤を適用する方法
PT1605956E (pt) 2002-12-18 2016-03-09 Centrexion Therapeutics Corp Administração de capsaicinóides para o tratamento da osteoartrite
US20040156931A1 (en) 2002-12-18 2004-08-12 Algorx Administration of capsaicinoids
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
RU2373953C2 (ru) 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EA200701131A1 (ru) * 2004-11-24 2007-12-28 Алгоркс Фармасьютикалз, Инк. Гелеобразная препаративная форма капсаициноида и способы её применения
DE502004011941D1 (de) 2004-12-22 2011-01-05 Mestex Ag Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
ES2533256T3 (es) 2004-12-28 2015-04-08 Mestex Ag Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor
EP1830835B1 (de) 2004-12-28 2012-03-14 Mestex AG Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan f]r die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
EP1865933B1 (en) * 2005-03-30 2015-11-04 Vanderbilt Royalty Sub L.P. Low-concentration capsaicin patch and methods for treating neuropathic pain
US20080160487A1 (en) 2006-12-29 2008-07-03 Fairfield Language Technologies Modularized computer-aided language learning method and system
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
CN101507818B (zh) 2008-12-15 2010-11-10 中国人民武装警察部队医学院 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20130303495A1 (en) 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
EP2552302B1 (en) * 2010-03-30 2020-07-01 The Children's Research Institute Apparatus and method for human algometry
EP3388057B1 (en) 2011-09-09 2022-03-09 Propella Therapeutics, Inc. A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof
US9566187B2 (en) 2012-03-13 2017-02-14 Breg, Inc. Cold therapy systems and methods
CA2868416A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release pharmaceutical compositions with abuse deterrent properties
ES2699806T3 (es) 2012-04-18 2019-02-12 SpecGx LLC Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
JP2015523401A (ja) 2012-08-03 2015-08-13 メステックス・アー・ゲー レシニフェラトキシン溶液
AU2013341380B2 (en) 2012-11-12 2018-04-26 Propella Therapeutics, Inc. Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
GB201317756D0 (en) 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US20150133561A1 (en) * 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
JP6487452B2 (ja) 2014-01-24 2019-03-20 センティス ファーマ プライベート リミテッド ブリンゾラミドを含む医薬組成物
US20170042834A1 (en) 2014-04-14 2017-02-16 Flex Pharma, Inc. Ion channel activators and methods of use
MX377377B (es) 2014-04-15 2025-03-10 Propella Therapeutics Inc Composiciones tópicas para el alivio del dolor, manufactura y uso.
CN105030760B (zh) 2014-04-24 2018-10-02 长弘生物科技股份有限公司 稳定医药组合物
JP6855248B2 (ja) 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
WO2015198350A1 (en) 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
KR20170066344A (ko) 2014-08-19 2017-06-14 만디쇼라 이스라엘 무자리 약제로서의 캡시노이드 및 그의 용도
JP2017534656A (ja) 2014-11-13 2017-11-24 セントレクシオン セラピューティクス コーポレイション 肢端舐性肉芽腫の治療に使用するためのカプサイシノイド
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
WO2016126540A1 (en) 2015-02-02 2016-08-11 Enspire Group LLC Stabilized dialkyl fumarate compositions
CA2987517A1 (en) 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
CA3254279A1 (en) 2015-06-03 2025-03-18 Triastek, Inc. PHARMACEUTICAL FORMS AND RELATED USES
WO2017087803A1 (en) 2015-11-20 2017-05-26 Sorrento Therapeutics, Inc. Methods for pain treatment using resiniferatoxin
EP3405187A4 (en) 2016-01-22 2019-07-31 Centrexion Therapeutics Corporation SEQUENCING DOSAGE METHOD FOR CAPSAICN FOR THE TREATMENT OF MORTON NEUROM
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
EP3463576A4 (en) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. PRODRUGS BY PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETIC AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA
KR102657458B1 (ko) * 2016-11-02 2024-04-12 센트렉시온 테라퓨틱스 코포레이션 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도
WO2018217937A1 (en) 2017-05-24 2018-11-29 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2019018769A1 (en) * 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE

Also Published As

Publication number Publication date
AU2018302342B2 (en) 2024-08-08
AU2018302342A1 (en) 2020-02-06
US11026903B2 (en) 2021-06-08
EP3654961A4 (en) 2021-04-21
EP3654961A1 (en) 2020-05-27
US20200206166A1 (en) 2020-07-02
JP2020527574A (ja) 2020-09-10
JP7738031B2 (ja) 2025-09-11
IL272036A (en) 2020-03-31
EP3654961C0 (en) 2025-01-08
EP3654961B1 (en) 2025-01-08
US20250312298A1 (en) 2025-10-09
WO2019018769A1 (en) 2019-01-24
US12201594B2 (en) 2025-01-21
JP2023116457A (ja) 2023-08-22
CA3069540A1 (en) 2019-01-24
ES3018268T3 (en) 2025-05-14
IL272036B1 (en) 2024-09-01
US20210299072A1 (en) 2021-09-30
CN111201015A (zh) 2020-05-26
JP7282736B2 (ja) 2023-05-29
US20200360314A1 (en) 2020-11-19
IL272036B2 (en) 2025-01-01
BR112020000989A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
MX2020000488A (es) Metodos y composiciones para el tratamiento del dolor usando capsaicina.
MY199903A (en) Combination therapy with controlled-release cnp agonists
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
SG10201902664RA (en) Combination therapy for treating cancer
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX368387B (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
SA519401933B1 (ar) تركيبات صيدلية تحتوي على الأنسولين
AR105712A1 (es) Composiciones de insulina de rápida acción
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MX395613B (es) COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER.
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos
MX2021004463A (es) Terapia de disminución de arginina para el tratamiento de la deficiencia de gamt.
WO2015035410A8 (en) Cancer therapy
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo